BMEA vs. ALLO, CADL, ACB, IMMP, CRDF, FENC, SLRN, MNPR, PRQR, and NBTX
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Allogene Therapeutics (ALLO), Candel Therapeutics (CADL), Aurora Cannabis (ACB), Prima BioMed (IMMP), Cardiff Oncology (CRDF), Adherex Technologies (FENC), Acelyrin (SLRN), Monopar Therapeutics (MNPR), ProQR Therapeutics (PRQR), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical products" industry.
Biomea Fusion vs. Its Competitors
Biomea Fusion (NASDAQ:BMEA) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
Allogene Therapeutics' return on equity of -52.98% beat Biomea Fusion's return on equity.
Biomea Fusion has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500.
Biomea Fusion has higher earnings, but lower revenue than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.
In the previous week, Allogene Therapeutics had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Allogene Therapeutics and 2 mentions for Biomea Fusion. Allogene Therapeutics' average media sentiment score of 1.52 beat Biomea Fusion's score of 1.14 indicating that Allogene Therapeutics is being referred to more favorably in the news media.
96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 18.4% of Biomea Fusion shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Biomea Fusion currently has a consensus target price of $21.40, indicating a potential upside of 1,102.25%. Allogene Therapeutics has a consensus target price of $8.44, indicating a potential upside of 581.00%. Given Biomea Fusion's stronger consensus rating and higher probable upside, research analysts plainly believe Biomea Fusion is more favorable than Allogene Therapeutics.
Summary
Allogene Therapeutics beats Biomea Fusion on 8 of the 15 factors compared between the two stocks.
Get Biomea Fusion News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
This page (NASDAQ:BMEA) was last updated on 7/15/2025 by MarketBeat.com Staff
Free BMEA Stock Alerts